Chimerix (NASDAQ:CMRX) Now Covered by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Chimerix (NASDAQ:CMRX) in a research report sent to investors on Tuesday. The brokerage issued a hold rating on the biopharmaceutical company’s stock.

A number of other research firms have also recently commented on CMRX. HC Wainwright reissued a “neutral” rating and issued a $8.55 price target (down from $11.00) on shares of Chimerix in a report on Wednesday, March 5th. Jefferies Financial Group restated a “hold” rating and set a $8.50 target price (down previously from $10.00) on shares of Chimerix in a research report on Wednesday, March 5th. Finally, Wedbush reiterated a “neutral” rating and issued a $8.55 price target (up from $7.00) on shares of Chimerix in a report on Wednesday, March 5th.

Chimerix Price Performance

CMRX opened at $8.51 on Tuesday. The firm has a market cap of $798.27 million, a P/E ratio of -9.05 and a beta of -0.17. Chimerix has a 1-year low of $0.75 and a 1-year high of $8.54. The company has a 50 day simple moving average of $6.58 and a two-hundred day simple moving average of $3.53.

Chimerix (NASDAQ:CMRX) last issued its quarterly earnings results on Friday, March 21st. The biopharmaceutical company reported ($0.25) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.01. The business had revenue of $0.06 million during the quarter, compared to analysts’ expectations of $0.31 million. Equities analysts anticipate that Chimerix will post -0.99 earnings per share for the current year.

Insider Transactions at Chimerix

In related news, CEO Michael T. Andriole sold 7,370 shares of the stock in a transaction dated Thursday, February 13th. The shares were sold at an average price of $4.52, for a total value of $33,312.40. Following the completion of the transaction, the chief executive officer now owns 609,603 shares of the company’s stock, valued at approximately $2,755,405.56. This trade represents a 1.19 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders have sold 20,760 shares of company stock valued at $91,175 in the last ninety days. Corporate insiders own 13.10% of the company’s stock.

Institutional Investors Weigh In On Chimerix

Several institutional investors have recently modified their holdings of CMRX. Bender Robert & Associates purchased a new stake in Chimerix during the 4th quarter valued at $37,000. Susquehanna Fundamental Investments LLC bought a new position in Chimerix during the fourth quarter valued at $59,000. Jane Street Group LLC purchased a new stake in shares of Chimerix in the fourth quarter valued at $62,000. Diadema Partners LP bought a new stake in shares of Chimerix in the 4th quarter worth about $101,000. Finally, Squarepoint Ops LLC purchased a new position in shares of Chimerix during the 4th quarter worth about $130,000. 45.42% of the stock is owned by institutional investors.

About Chimerix

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.